Oncolys BioPharma Inc. (TYO:4588)
7,460.00
-160.00 (-2.10%)
Nov 18, 2026, 10:50 AM JST
Oncolys BioPharma Revenue
Oncolys BioPharma had revenue of 24.72M JPY in the quarter ending September 30, 2026, a decrease of -13.41%. This brings the company's total for the last twelve months to 28.55M, down -9.04% year-over-year. In the year 2024, Oncolys BioPharma had annual revenue of 31.38M, down -50.21%. That makes Oncolys BioPharma the 45,632nd largest company in the world by revenue and 3,872nd in Japan.
Revenue (ttm)
28.55M
Revenue Growth
-9.04%
P/S Ratio
7,887.49
Revenue / Employee
679.67K
Employees
45
Market Cap
220.43B
Revenue by Geography
- Japan 35.00M 55.5%
- United States of America 28.04M 44.5%
Fiscal year ended Dec 31, 2023 See the full Oncolys BioPharma breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.38M | -31.65M | -50.21% |
| Dec 31, 2023 | 63.04M | -913.14M | -93.54% |
| Dec 31, 2022 | 976.18M | 333.69M | 51.94% |
| Dec 31, 2021 | 642.49M | 328.32M | 104.50% |
| Dec 31, 2020 | 314.18M | -989.67M | -75.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GNI Group | 37.21B |
| Nxera Pharma | 35.51B |
| PeptiDream | 20.48B |
| 3-D Matrix | 11.92B |
| RaQualia Pharma | 4.02B |
| Heartseed | 3.03B |
| Japan Tissue Engineering | 2.68B |
| Cuorips | 72.00M |